This film tells the story of the journey from research to practice for self-injectable contraception in Malawi.
From 2015 to 2017, FHI 360 and the University of Malawi conducted a study in Malawi to investigate the effectiveness of self-administered depot medroxyprogesterone acetate (DMPA-SC). The study found that self-injection led to a more than 50% increase in continuous DMPA-SC pregnancy protection through 12 months, compared to provider-administered injection.
As a result of the study findings, the Ministry of Health in Malawi are now rolling out DMPA-SC and self-injection in 7 districts across the country, with plans for national scale-up by 2020. This self-injectable contraception puts power in the hands of girls and women to make decisions and take control of their own health, accelerating universal access to sexual and reproductive healthcare.
FIlm made in partnership with Children's Investment Fund Foundation: CIFF, FHI 360 and USAID.
The study is available to read in full on The Lancet Global Health website: